Mombaerts I, Schlingemann R O, Goldschmeding R, Koornneef L
Department of Ophthalmology, University of Amsterdam, The Netherlands.
Ophthalmology. 1996 Mar;103(3):521-8. doi: 10.1016/s0161-6420(96)30663-5.
Systemic corticosteroids are the established primary treatment for orbital pseudotumors, but patients with recurrent and refractory pseudotumors commonly are observed. In this retrospective study, the authors aimed to assess the value of corticosteroids in the management of orbital pseudotumor.
The clinical notes, computed tomography scans, and histologic specimens of patients with orbital pseudotumor seen at the Orbital Center, Amsterdam, between 1976 and 1994 were analyzed with particular regard to the clinical and visual outcome. The patients were categorized according to the anatomic location of the pseudotumor within the orbit. Patients with pseudotumors restricted to the lacrimal gland or an extraocular muscle were excluded.
The authors studied 32 patients with orbital pseudotumor, 20 of whom had histopathologic confirmation. Twenty-seven of these 32 patients received systemic corticosteroids as an initial treatment. Of these 27 patients, 21 (78%) showed an initial response and 10 (37%) obtained a cure. After the initial response, 11 (52%) of the 21 patients recurred. Optic nerve involvement was present in 13 (41%) of the 32 patients, and all except 1 patient recovered with corticotherapy. The mean follow-up of therapy was 4.3 years (range, 5.3 months-21.5 years).
The authors found a moderate response, a high recurrence, and a low cure rate in patients treated with corticosteroids for orbital pseudotumor, and they therefore challenge the value of corticosteroids in both diagnosing and treating this condition. However, in patients with pseudotumor-induced optic neuropathy, corticosteroids remain of value.
全身用皮质类固醇是眼眶假瘤既定的主要治疗方法,但对于复发性和难治性假瘤患者通常采用观察治疗。在这项回顾性研究中,作者旨在评估皮质类固醇在眼眶假瘤治疗中的价值。
分析了1976年至1994年间在阿姆斯特丹眼眶中心就诊的眼眶假瘤患者的临床记录、计算机断层扫描和组织学标本,特别关注临床和视觉结果。根据假瘤在眼眶内的解剖位置对患者进行分类。局限于泪腺或眼外肌的假瘤患者被排除。
作者研究了32例眼眶假瘤患者,其中20例有组织病理学证实。这32例患者中有27例接受了全身皮质类固醇作为初始治疗。在这27例患者中,21例(78%)显示出初始反应,10例(37%)治愈。在初始反应后,21例患者中有11例(52%)复发。32例患者中有13例(41%)出现视神经受累,除1例患者外,所有患者经皮质类固醇治疗后均康复。治疗的平均随访时间为4.3年(范围为5.3个月至21.5年)。
作者发现,接受皮质类固醇治疗的眼眶假瘤患者反应中等、复发率高且治愈率低,因此他们质疑皮质类固醇在诊断和治疗这种疾病中的价值。然而,对于假瘤引起的视神经病变患者,皮质类固醇仍然有价值。